Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Treatment of chronic urticaria
Autore:
Merk, HF;
Indirizzi:
Rhein Westfal TH Aachen, Univ Klin Dermatol & Allergol, D-5100 Aachen, Germany Rhein Westfal TH Aachen Aachen Germany D-5100 ol, D-5100 Aachen, Germany
Titolo Testata:
ALLERGOLOGIE
fascicolo: 10, volume: 24, anno: 2001,
pagine: 491 - 502
SICI:
0344-5062(200110)24:10<491:TOCU>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
GER
Soggetto:
CHRONIC IDIOPATHIC URTICARIA; DELAYED PRESSURE URTICARIA; DOUBLE-BLIND CROSSOVER; HUMAN-SKIN; 2ND-GENERATION ANTIHISTAMINES; HISTAMINE-RELEASE; CONTROLLED TRIAL; COLD URTICARIA; MAST-CELLS; ANTAGONISTS;
Keywords:
urticaria; antihistamines; DADPS; glucocorticoids; IVIG;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
96
Recensione:
Indirizzi per estratti:
Indirizzo: Merk, HF Rhein Westfal TH Aachen, Fak Med, Hautklin, Pauwelsstr 30, D-52074 Aachen,Germany Rhein Westfal TH Aachen Pauwelsstr 30 Aachen Germany D-52074 any
Citazione:
H.F. Merk, "Treatment of chronic urticaria", ALLERGOLOGI, 24(10), 2001, pp. 491-502

Abstract

Major progress has been achieved in our understanding of the pathophysiology of different forms of chronic urticaria during the last years. Most important is the understanding of chronic urticaria as a symptom than as a disease. This symptom is the result of a malfunction of basophiles and/or mast cells resulting in an increased release of histamine and other inflammatorymediators by these cells. The causes are quite different and include the release of these agents by toxic events induced by specific drugs or other substances known to be histamine releasers, allergic reactions which are in most cases IgE-mediated and autoimmune reactions. This progress resulted also in new therapeutic options such as cyclosporin A, intravenous immunoglobulin, plasmaphereses, chloroquine, sulfones, calcium antagonists, although antihistamines are still the first-line drugs in by far most cases of chronic urticaria. Therefore, the development of new antihistamines with less side effects, such as the antihistamines of the "second generation" or the latest development leading to fexofenadin, descarboxyloratadine and levoceterezine, compounds which establish a third generation of antihistamines in the treatment of urticaria.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/04/20 alle ore 07:46:49